Sponsors & Exhibitors
Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world. This commitment to transform lives is more than a goal. It’s fulfilling the brand promise by focusing on solutions that matter most, pursuing excellence and collaborating with healthcare professionals to provide a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. As a global medical technology leader, Boston Scientific proudly celebrates 40 years transforming lives and making a difference to more people in more places around the world live longer, healthier lives.
Through innovation and collaboration, Medtronic improves the lives and health of millions of people each year. We offer the broadest range of innovative medical technology and services for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. Learn more about our technology, services and solutions at Medtronic.com.
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 103,000 colleagues serve people in more than 160 countries.
Biosense Webster, a division of Johnson & Johnson Medical NV/SA, is a global leader in the science of diagnosing and treating heart rhythm disorders and has pioneered the development of Atrial Fibrillation treatment for over 20 years. The company partners with clinicians to develop innovative technologies that improve the quality of care for arrhythmia patients worldwide. With a 22-year legacy of expertise in electrophysiology, Biosense Webster’s mission is to deliver breakthrough innovations that help restore a patient’s regular heart rhythm. More information can be found at www.biosensewebster.com.
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to medicines for cardiovascular diseases, Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.
Improving the health and quality of life of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 18.1 per cent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.
More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.
Bayer is a global enterprise with a more than 150-year history and core competencies in the Life Science fields of health care and nutrition. The company’s headquarter is located in Leverkusen, Germany.
The Pharmaceuticals Division focuses on researching, developing and marketing specialty-focused innovative medicines that provide significant clinical benefit and value, primarily in the therapeutic areas of cardiology, oncology, hematology, ophthalmology and women’s healthcare. The division also comprises of the Diagnostic Imaging business which markets contrast agents. In this way, our products are designed to overcome the major challenges presented by a growing and aging global population.
Bayer Thai Co., Ltd, established since 1962, has been committed to continuously bring in innovate medicine to address high unmet need for medical treatments in Thailand.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. Pfizer (Thailand) Limited, established in 1958, is one of Thailand’s largest biopharmaceutical companies that committed to bring breakthroughs that change patients’ lives. For more than 60 years, Pfizer (Thailand) has been offering innovative, high quality medicines and medical supplies to prevent and treat disease and improve the health and wellness of Thais. We expand access to quality medicines to provide better health care support through collaborative partnerships with healthcare providers, medical professionals, public and private organizations, and local communities across Thailand.